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As survival rates in allogeneic hematopoietic stem cell transplantation (HSCT) continue to improve, attention
to long-term complications, including cardiovascular disease, becomes a major concern. Cardiovascular
disease and dyslipidemia are a common, yet often overlooked occurrence post-HSCT that results in signiﬁcant
morbidity and mortality. Also, increasing evidence shows that several anti-hyperlipidemia medications, the
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in particular, may have a role in modulating
graft-versus-host disease (GVHD). However, factors such as drugedrug interactions, adverse effect proﬁles,
and the relative efﬁcacy in lowering cholesterol and triglyceride levels must be taken into account when
choosing safe and effective lipid-lowering therapy in this setting. This review seeks to provide guidance to the
clinician in the management of dyslipidemia in the allogeneic HSCT population, taking into account the
recently published American College of Cardiology/American Heart Association guidelines on hyperlipidemia
management, special considerations in this challenging population, and the evidence for each agent’s
potential role in modulating GVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stemcell transplantation (HSCT)
represents a potentially curative therapy for a number of life-
threatening conditions. Because of advances in patient care,
survival outcomes in allogeneic HSCT have improved sub-
stantially over the years [1-3]. The National Marrow Donor
Program analysis reported that 1-year survival rates for pa-
tients receiving a transplant from an unrelated donor have
increased from 42.2% from 1996 to 2001 to 61.8% in the most
recent 2008-2010 dataset [4]. Survival for unrelated donor
transplants has even been shown to be comparable with
related donor transplants in certain populations [5-7]. With
continued improvements in HLA matching, supportive care
measures, and control of graft-versus-host disease (GVHD),
this trend is not expected to cease. Despite this improvement
in peritransplant and immediate post-transplant survival, life
expectancy for patients who survive more than 5 years
post-transplant is approximately 30% lower than thedgments on page 818.
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ty for Blood and Marrow Transplantation.general population, regardless of age [8]. This excessmortality
has been attributed to the many long-term complications
of allogeneic HSCT, including chronic GVHD, infection, and
end-organ dysfunction, which may affect the respiratory,
endocrine, hepatic, skeletal, ophthalmologic, renal, and car-
diovascular systems [9].
Cardiovascular disease (CVD) is one of the more signiﬁ-
cant long-term complications of allogeneic HSCT, contrib-
uting to considerable morbidity and mortality [10-14]. Risk
factors for CVD in the general population include age,
hypertension, smoking, diabetes, and dyslipidemia [15].
Hypertension and smoking are the leading risk factors in
terms of attributable mortality (13% and 9% of annual global
deaths, respectively) [16]. However, these risk factors tend
to cluster together, and dyslipidemia is estimated to be
responsible for approximately 2.6 million deaths (4.5% of
attributable global deaths) and one third of ischemic heart
disease globally [16]. Management of modiﬁable cardio-
vascular risk factors, particularly dyslipidemia, can be
challenging in the allogeneic HSCT population. Pharmaco-
logic agents for dyslipidemia are not without serious side
effects, and there are a number of clinically signiﬁcant drug
interactions the transplant provider must take into account.
In a population particularly prone to adverse reactions and
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comes increasingly important.
Growing evidence also shows that statins and other anti-
hyperlipidemia medications possess immunomodulatory
properties; thus, the choice of lipid-lowering agent may have
implications for GVHD outcomes post-transplant [17]. No
guidelines exist at this time for the treatment of hyperlip-
idemia in allogeneic HSCT patients, and because of increasing
survival post-transplant, a growing number of these in-
dividuals are no longer under the continuous care of trans-
plant centers. Thus, awareness of the magnitude of
cardiovascular risk and optimal pharmacotherapy of dysli-
pidemia in this challenging patient population is crucial. In
this review, we summarize literature surrounding the
treatment of dyslipidemia in allogeneic HSCT patients, with a
focus on pharmacotherapy and the potential for immuno-
modulation with anti-hyperlipidemia medications.
SCOPE OF THE PROBLEM IN HSCT PATIENTS
In 2011, an international HSCT working group convened
to update the recommendations for screening and preven-
tive practices in long-term survivors of HSCT [18]. They noted
that compared with other post-transplant complications,
CVD is relatively rare. However, the notion that cardiovas-
cular complications after HSCT may be underestimated was
acknowledged [18]. Indeed, based on the most recent data
available, this appears to be the case. The increased cardio-
vascular risk among survivors of HSCT was ﬁrst well
described in 2007 by Baker et al. [19]. In a retrospective
analysis, 1089 survivors of HSCT were evaluated using 389
siblings as a matched control group. The age- and body mass
indexeadjusted risk of diabetes mellitus and hypertension
were 2 to 3 times higher (odds ratios, 2.31 [95% conﬁdence
interval, 1.45 to 3.67] and 3.42 [95% conﬁdence interval, 1.55
to 7.52], respectively) in allogeneic HSCT patients. Another
retrospective cohort study of 85 long-term survivors of HSCT
found a similar high risk of CVD and metabolic syndrome
(according to National Cholesterol Education Program-Adult
Treatment Panel III criteria) [13]. The prevalence of metabolic
syndrome was approximately double that expected from an
age-adjusted general population cohort (29 cases versus 12.8
expected, P< .0001). Hypertriglyceridemia was present in 24
of 29 cases of metabolic syndrome in the HSCT group [13].
Not only is the risk of CVD greater in patients post-HSCT,
evidence increasingly shows that the onset of CVD in HSCT
patients occurs more quickly. A retrospective single-center
cohort study by Tichelli et al. [12] found a cumulative
incidence of CVD of 22% at 25 years, with a median age at
onset of 49 years for the ﬁrst cardiovascular event. Hyper-
lipidemia was associated with the development of CVD in a
univariate analysis, and in a multivariate analysis the pres-
ence of 2 or more cardiovascular risk factors, including
hyperlipidemia, was associated with the development of
CVD [12]. A larger, multicenter, retrospective cohort study
found similar premature adverse cardiovascular outcomes
after HSCT, and the median age at onset was 54 [11]. The
presence of hyperlipidemia was signiﬁcantly associated
with the incidence of an arterial cardiovascular event within
15 years post-transplant (12% versus 2%, P ¼ .0001) [11]. A
nested case-control study of 3287 consecutive patients who
survived at least 1 year post-transplant also found that
post-HSCT hyperlipidemiawas a risk factor for development
of CVD [14]. Thus, HSCT patients are at risk for premature
CVD, and hyperlipidemia is a signiﬁcant risk factor for this
serious post-transplant complication.An analysis by Kagoya et al. [20] sought to characterize the
prevalence and risk factors for dyslipidemia in allogeneic
HSCT patients. Of the 194 adult patients followed for amedian
of 77 months, 42.8% developed hypercholesterolemia and
50.8% developed hypertriglyceridemia. Again, the onset of
dyslipidemia was rapid, with the median interval to occur-
rence of hypercholesterolemia andhypertriglyceridemia of 11
and 8 months post-allogeneic HSCT, respectively. In a multi-
variate analysis, family history of hyperlipidemia, the inci-
dence of chronic GVHD, chronic liver disease, and steroid use
were all independently associated with the development of
hypercholesterolemia.
The most comprehensive analysis of the incidence and
course of hyperlipidemia post-allogeneic HSCT to date was a
retrospective chart review by Blaser et al. [21] of 761 patients
who survived >100 days after allogeneic HSCT and had lipid
measurements in the post-transplant period. Patients
received tacrolimus-based GVHD prophylaxis, and sirolimus
was included in 50% of regimens. The incidence of dyslipi-
demia post-transplant was substantial; 73.4% of patients
developed hyperlipidemia and 72.5% hypertriglyceridemia. In
a multivariate analysis, being overweight and developing
grades II to IV acute GVHD were both associated with post-
transplant hyperlipidemia and hypertriglyceridemia. Among
those with grades II to IV acute GVHD, 81% with hyperlipid-
emia and 73% with hypertriglyceridemia were on cortico-
steroids at the time of peak lipid and triglyceride values. As
survival outcomes continue to improve post-HSCT, manage-
ment of long-term complications becomes increasingly
important. Clearly, the preponderance of the literature sug-
gests that the risk of hyperlipidemia and adverse cardiovas-
cular outcomes post-transplant are signiﬁcant and worthy of
treatment consideration.
PATHOPHYSIOLOGY
CVD and coronary artery disease involves a complex
interplay between a number of factors, including obesity,
dyslipidemia, and inﬂammation [22]. Adipose tissue in-
creases the production of inﬂammatory cytokines and
chemokines, including monocyte chemotactic protein 1
(MCP-1), tumor necrosis factor (TNF)-a, and IL-6 [23]. Free
fatty acids released by adipose tissue also generate reactive
oxygen species, leading to the oxidation of low-density li-
poprotein (LDL) [23]. The oxidized LDL is ultimately taken up
by activated macrophages, leading to the formation of foam
cells characteristic of atherosclerotic lesions. Oxidized LDL
also promotes endothelial activation, adhesion molecule
expression, a reduction in vasodilator production (nitric ox-
ide), and recruitment of platelets and inﬂammatory cells
[23]. Such an inﬂammatory environment promotes plaque
instability, ultimately resulting in plaque rupture, thrombus
formation, and infarction [22]. Thus, both inﬂammation and
dyslipidemia contribute signiﬁcantly to the development of
coronary artery disease.
The pathophysiology of dyslipidemia in allogeneic HSCT
patients is multifactorial. Allogeneic HSCT patients are on
immunosuppression for extended periods of time, and many
of these agents are well known for altering lipid homeostasis.
Sirolimus, amammalian target of rapamycin (mTOR) inhibitor
used both for the prevention and treatment of GVHD, is
associated with a high incidence of hyperlipidemia and
hypertriglyceridemia [24]. Sirolimus, in its original studies in
renal transplantation, was associated with a 45% to 57% inci-
dence of hypertriglyceridemia and a 43% to 46% incidence
of hyperlipidemia at over 1 year post-transplant [24].
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more pronounced in allogeneic HSCT patients. In a study by
Couriel et al. [25], the use of sirolimus in the treatment of
steroid refractory chronic GVHD was associated with a 77%
incidence of hypertriglyceridemia and a 34% incidence of
hypercholesterolemia. Many of these patients had pro-
nounced dyslipidemia. For example, 44% of patients with
hypertriglyceridemia had levels 2 to 5 times the upper limit of
normal and half of patients with hyperlipidemia had levels
greater than 11.637 mmol/L (normal level, <5.172 mmol/L).
Lipid abnormalities were also quick to arise, occurring within
1 month of initiation of therapy. Sirolimus-induced hyper-
lipidemia may involve several different mechanisms [26-29].
Morrisett et al. [26] found that sirolimus treatment resulted in
a dose-dependent expansion of the free fatty acid pool and an
increase in hepatic very-low-density lipoprotein (VLDL) syn-
thesis. This study and several other analyses of lipid meta-
bolism indicate that inhibition ofmTOR by sirolimus results in
increased lipolysis via augmentation of hormone-sensitive
lipase (increasing circulating free fatty acids), interference
with triglyceride metabolism, decreased triglyceride storage,
and a disruption of the insulin-signaling pathway [26-29].
The calcineurin inhibitor cyclosporine is also associated
with lipid abnormalities. A double-blind, randomized,
placebo-controlled trial of 36 nontransplanted patients
treated with cyclosporine for only 2 months resulted in 21%
and 31% mean increases in total cholesterol and LDL,
respectively [30]. It is thought that cyclosporine impairs the
conversion of cholesterol into bile acids via inhibition of
steroid 26-hydroxylase. Furthermore, cyclosporine, trans-
ported by lipoproteins, has been shown to block LDL re-
ceptors, resulting in an elevated serum LDL [31]. Finally,
similar to sirolimus, cyclosporine has been shown to affect
VLDL and LDL clearance via alterations in lipase activities [31].
Tacrolimus, a calcineurin inhibitor with more potent
immunosuppressive activity than cyclosporine, may induce
less hyperlipidemia when compared with cyclosporine. For
example, in kidneyepancreas transplant recipients with
elevated pretransplant lipid values, tacrolimus-based
immunosuppression resulted in signiﬁcant reductions in
serum cholesterol and triglycerides to levels consistent with
the general population, indicating tacrolimus may have a
lipid-neutral effect [32]. Crossover studies in solid organ
transplant switching from cyclosporine- to tacrolimus-based
immunosuppression have resulted in improved lipid values,
further demonstrating the potential differences between the
2 calcineurin inhibitors’ effects on lipid metabolism [31].
Large phase III studies in allogeneic HSCT patients, however,
have not reported differences in rates of hyperlipidemia be-
tween cyclosporine- and tacrolimus-treated patients [33-35].
Glucocorticoids, often used in high doses for the treat-
ment of GVHD, besides being known for their hyperglycemic
and appetite-stimulating effects, are also associated with the
development of dyslipidemia. Indeed, the study by Blaser
et al. [21] discussed above found that although acute GVHD
was associated with the development of hyperlipidemia and
hypertriglyceridemia post-transplant, most of these patients
were on corticosteroids at the time of peak measurements.
Thus, in this setting, corticosteroids may be the underlying
cause of dyslipidemia. The mechanism by which cortico-
steroids cause dyslipidemia is multifactorial. They result in
alterations in lipase activity, increases in de novo lipogen-
esis, and an increase in VLDL export, resulting in increased
cholesterol and triglyceride levels [36]. Furthermore,
glucocorticoids down-regulate the LDL receptor, furtherperturbing lipid levels [31]. An excellent review of gluco-
corticoid effects on lipid metabolism has been published,
and a full discussion of the impact of glucocorticoids on lipid
and glucose homeostasis is beyond the scope of this
review [36].
Not only do immunosuppressants contribute to dyslipi-
demia in allogeneic HSCT patients, but post-transplant com-
plications can also affect lipid homeostasis. For example,
chronic GVHD of the liver can result in severe elevations in
serum total cholesterol and triglycerides, caused by the
inability of bile salts and cholesterol to be cleared through the
bile duct. This causes a backup of cholesterol into the serum,
transportedbyanabnormal lipoproteinparticle, lipoproteinX
[37]. Nephrotic syndrome, a rare but serious complication
associated with chronic GVHD, has also been known to cause
signiﬁcant dyslipidemia [38,39]. Finally, post-transplant
endocrine complications, including hypogonadism and hy-
pothyroidism, are well known to contribute to dyslipidemia
[40,41]. These abnormalities are particularly common in
those patients who receive total body irradiation as a part of
the conditioning regimen [9]. Thus, both immunosuppres-
sants and the transplant process itself contribute to the
pathogenesis of dyslipidemia in allogeneic HSCT patients.
TREATMENT
Traditionally, the paradigm in the management of dysli-
pidemia has been to treat to an LDL target. However, the ideal
target LDL has not been established. It has been assumed that
the lower the LDL cholesterol, the better, but this does not
take into account the potential for increased adverse events
with increasing doses of drugs and implementing combina-
tion drug therapy to achieve LDL goals. Clearly, this approach
was not supported by strong clinical evidence. In November
2013 the American Heart Association (AHA) released new
cholesterol management guidelines that replace the older
National Heart, Lung and Blood Institute guidelines [42].
Although lifestyle modiﬁcations remain a critical component
to therapy and risk reduction, the new guidelines simplify
management by focusing on treating patients who are most
likely to beneﬁt from drug therapy based on the literature.
According to the guidelines, 4 groups of patients should
be treated with statin therapy: (1) patients with clinical
atherosclerotic CVD (coronary heart disease, stroke, and pe-
ripheral artery disease), (2) patients with familial (primary)
hyperlipidemia and an LDL > 4.913 mmol/L (normal level,
<2.586 mmol/L), (3) patients age 40 to 75 years with type 2
diabetes, and (4) patients with an estimated 10-year cardio-
vascular risk 7.5% [42]. The Pooled Cohort Risk Assessment
Equations developed by the AHA’s Risk Assessment Work
Group are used to estimate this risk and are available online
as a downloadable spreadsheet on the AHA website (http://
my.americanheart.org/professional/StatementsGuidelines/
PreventionGuidelines/Prevention-Guidelines_UCM_45769
8_SubHomePage.jsp) [42].
Most patients in these categories should be treated with
moderate- or high-intensity statin therapy, taking into ac-
count the patient’s age, ability to tolerate high-intensity
statin therapy (eg, drugedrug interactions, history of statin
intolerance), and clinical trial evidence. Statins that lower
LDL by more than 50% on average are considered high-
intensity statins, and those that lower LDL by approxi-
mately 30% to 50% are considered moderate-intensity statins
(Table 1) [42]. Because there is less evidence for nonstatin
drugs, and trials to date have not demonstrated signiﬁcant
reductions in atherosclerotic CVD, the guidelines do not
Table 1
Classiﬁcation of Statin Therapy
High-Intensity
Statin Therapy
Daily Dose Lowers
LDL > 50%
Moderate-Intensity
Statin Therapy
Daily Dose Lowers
LDL 30%-50%
Low-Intensity
Statin Therapy
Daily Dose Lowers
LDL < 30%
Atorvastatin 40-80 mg
Rosuvastatin 20-40 mg
Atorvastatin 10-20 mg
Rosuvastatin 5-10 mg
Simvastatin 20-40 mg
Pravastatin 40-80 mg
Lovastatin 40 mg
Fluvastatin 40 mg b.i.d.
(or XL 80 mg daily)
Pitavastatin 2-4 mg
Simvastatin 10 mg
Pravastatin 10-20 mg
Lovastatin 20 mg
Fluvastatin 20-40 mg
Pitavastatin 1 mg
Data from [42].
B.L. Marini et al. / Biol Blood Marrow Transplant 21 (2015) 809e820812support the routine use of these agents. However, in patients
who are unable to completely tolerate statin therapy, the
addition of nonstatin cholesterol-lowering therapy may be
considered [42]. Furthermore, in patients with very high
triglyceride levels or with a history of triglyceride-induced
pancreatitis, nonstatin therapies (eg, ﬁbrates, niacin, n-3
polyunsaturated fatty acids) are reasonable in addition to
intensive therapeutic lifestyle changes [43]. Table 2 sum-
marizes the AHA recommendations for the treatment of
hyperlipidemia.
From the evidence discussed thus far, it is clear that
allogeneic HSCT patients are at a signiﬁcantly higher risk of
early CVD relative to the general population [11-14]. To put
the numbers in context with the new AHA guidelines and
the 7.5% cutoff, the retrospective analysis of allogeneic HSCT
patients by Tichelli et al. [12] demonstrated a 4.1% rate of
CVD at 10 years. The 7.5% cutoff in the AHA guidelines was
based on placebo group cardiovascular event rates from
large, multicenter trials that demonstrated a signiﬁcant
reduction in the risk of major cardiovascular events with
statin therapy in patients without baseline CVD [42]. Of
note, patients were signiﬁcantly older in these trials (mean
age of 58 in the MEGA and AFCAPS/TexCAPS trials and me-
dian age of 66 in the JUPITER trial) compared with a median
age of 27 in the Tichelli et al. study of allogeneic HSCT pa-
tients [12,44-46]. When adjusting for age, allogeneic HSCT
patients have an almost 7-fold increase in the risk of an
arterial cardiovascular event [12]. To further illustrate the
profound increase in CVD, at 25 years post-transplant,
where the age of patients is similar to those in the statin
primary prevention trials, the cumulative incidence of CVD
was 22% [12]. Based on the signiﬁcantly increased age-
adjusted risk for CVD in this population, it appears thatTable 2
Recommendations for Statin Therapy
Indications for Statin Therapy Clinical
Considerations
Recommendation
Clinical ASCVD Age  75 yr High-intensity statin
Age > 75 yr Moderate-intensity
statin
FH with LDL  4.913 mmol/L High-intensity statin
Diabetes, ages 40-75 yr 10-year ASCVD
risk < 7.5%
Moderate-intensity
statin
10-year ASCVD
risk  7.5%
High-intensity statin
7.5% estimated 10-year
ASCVD risk, ages 40-75 yr
Moderate- to high-
intensity statin
Data from [42]. ASCVD indicates atherosclerotic CVD; FH, familial (primary)
hyperlipidemia.treatment of all allogeneic HSCT patients able to tolerate
moderate- to high-intensity statin therapy is reasonable and
in line with AHA guidelines for targeting high-risk patients.
Long-term post-transplant adverse outcomes such as
these are likely to become increasingly important as strate-
gies in the management and prevention of GVHD continue to
be optimized. As the studies by Blaser et al. [21] and Kagoya
et al. [20] indicated, development of GVHD is associated
with the development of hyperlipidemia post-transplant.
Although this may be related to increased immunosuppres-
sion to manage GVHD, the role of inﬂammation in CVD and
atherosclerosis has been well described [47]. Both inﬂam-
mation due to the alloimmune process of GVHD and the high
prevalence of hyperlipidemia post-HSCT may contribute to
the negative cardiovascular outcomes in this population.
Theoretically, the reverse may also be true. Inﬂammatory
cytokines known to be involved in the process of athero-
sclerosis, including TNF-a and IL-6, are also those involved in
the development of GVHD [47,48]. Thus, a potential strategy
in the management of hyperlipidemia in HSCT could involve
agents that also target the inﬂammatory changes of both
atherosclerosis and GVHD. Furthermore, there is increasing
evidence that effector T cells rely on lipid-biosynthetic
pathways to meet the high metabolic demand of rapid
clonal expansion through a complex interplay of the sterol
regulatory element-binding proteins and liver X receptor
signaling [49-51]. This reliance on fat oxidation as a key fuel
source is not seen in homeostatic T cell proliferation or in the
hematopoietic stem cell population (which rely primarily on
aerobic glycolysis) [49,50]. Targeting hyperlipidemia in
allogeneic HSCT patients thus may help to limit the primary
fuel source of pathogenic T cells implicated in GVHD [52].
Finally, factors such as drugedrug interactions, adverse effect
proﬁles, and the relative efﬁcacy in lowering cholesterol and
triglyceride levels must be taken into consideration when
choosing safe and effective lipid-lowering therapy. The
remainder of this section discusses the pros and cons of the
various agents used in the treatment of hyperlipidemia and
the evidence for their use in this patient population.
Statins
Statins exert their anti-hyperlipidemic effects by
competitively inhibiting the rate-limiting enzyme in the
mevalonate pathway, 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase, preventing the conversion of
HMG-CoA to mevalonic acid [53]. This inhibition reduces
cholesterol production in the liver, resulting in an up-
regulation of LDL receptors and an increased clearance of
LDL from the blood [53]. Depending on the statin and dosage
used, these agents result in a 25% to 60% reduction in LDL
cholesterol and a 10% to 37% reduction in triglycerides in the
general population [54]. Thus, they are most effective in
patients with LDL-predominant hyperlipidemia.
The pleiotropic effects of statins have interested re-
searchers for decades, and these alternative mechanisms are
what makes these agents attractive for the treatment of
hyperlipidemia in allogeneic HSCT patients. The inhibition of
the mevalonate pathway not only reduces cholesterol syn-
thesis, but also decreases the isoprenylation and formation of
active cell signaling proteins, including Ras, Rac, and Rho [55].
This process preferentially skews CD4þ T cell differentiation
from a pro-inﬂammatory, T helper type 1 (TH1) phenotype
pathognomonic of acute GVHD to a noninﬂammatory TH2
phenotype. These effects were best demonstrated in a study
by Zeiser et al. [56] using a murine bone marrow transplant
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or recipient mice with atorvastatin provided partial protec-
tion from acute GVHD and resulted in 43% and 40% mean
survival rates, respectively, compared with a 0% survival rate
for placebo-treated mice. When both donor and recipient
mice were treated, the survival beneﬁt was additive, with a
65% survival rate in this group [56]. Because researchers were
able to show the protective effects of statins were reversed by
administration of mevalonate, it provides strong evidence
that inhibition of isoprenylation plays a signiﬁcant role in the
anti-GVHD effect of statins. Indeed, levels of prenylated RAS,
RAP-1, and Rho-B were reduced in T cells exposed to ator-
vastatin [56]. Zeiser et al. [56] also showed that, in vitro,
atorvastatin pretreatmentddespite promoting TH2 polariza-
tion in CD4þ T lymphocytesddid not impair the graft-versus-
tumor effects of cytotoxic T lymphocytes. Finally, statins have
been shown to induce the development of anti-inﬂammatory
T regulatory cells [57]. As a drug class, statins have the most
evidence for use in allogeneic HSCT patients; a retrospective
review of 761 allogeneic HSCT patients found that 29% of
patients were prescribed a statin within 2 years post-HSCT.
Use of statins in this population resulted in signiﬁcant re-
ductions in total cholesterol, LDL, and triglycerides with only
a 3% incidence of possible statin toxicity and only 1 case of
rhabdomyolysis [21].
Although prevention of isoprenylation clearly contributes
to the anti-GVHD effects of statins, additional immuno-
modulatory mechanisms involving T cell trafﬁcking and
costimulation have been described. Two agents in particular,
lovastatin and simvastatin, have been shown to inhibit
leukocyte function-associated antigen-1 (LFA-1), an integrin
molecule involved in regulating lymphocyte trafﬁcking and
activation. Activation of T cells induces a conformational
change in LFA-1, allowing it to bind with high afﬁnity to its
ligands on antigen-presenting cells (APCs), resulting in T cell
trafﬁcking and further activation [58]. Simvastatin andFigure 1. Mechanism of statin immunomodulation in GVHD [17,55-58,60,61]. Treg in
intercellular adhesion molecule; CIIA, MHC class II transactivator; TCR, T cell receptolovastatin bind allosterically to LFA-1, forcing it to remain in a
low-afﬁnity state. In a murine bone marrow transplantation
model, Wang et al. [59] were able to demonstrate that
blocking LFA-1 activation in recipient mice with lovastatin
resulted in a reduction in T cell homing to lymph nodes, a
decrease in donor derived Tcell proliferation, and, ultimately,
protection against acute GVHD mortality compared with
pravastatin controls. There is also abundant evidence that
statinsmay alter APC function and proliferation. In particular,
statins have been shown to reduce IFN-geinducedMHC class
II expression in APCs, decrease the expression of cos-
timulatory molecules and chemokine receptors on APCs, and
ultimately result in decreased APC maturation and activity
[17,60,61]. Figure 1 depicts the hypothesized immunomod-
ulatory activity of statins in the setting of GVHD.
In addition to the robust in vitro and animal data indi-
cating the potential utility of these agents in treating
hyperlipidemia and preventing GVHD, the evidence in allo-
geneic HSCT patients has been equally promising. The ﬁrst
indication that statins may be useful in the setting of allo-
geneic HSCT was actually a prospective trial evaluating the
effects of pravastatin in the treatment of refractory chronic
GVHD [62]. In this study, 18 patients with pathology-proven
chronic GVHD that did not respond to corticosteroids or
cyclosporine were treated with pravastatin titrated to a
maximum dose of 40 mg/day for 8 weeks. Pravastatin
treatment was associated with a signiﬁcant reduction in
serum total cholesterol (6.36mmol/L to 4.75mmol/L [normal
level <5.17 mmol/L], P ¼ .0001) and an overall response rate
of 28% in chronic GVHD scores [62]. In the setting of acute
GVHD, Hamadani et al. [63] conducted a retrospective anal-
ysis assessing the impact of statin use on 67 patients who
underwent allogeneic HSCT for acute leukemia. Patients who
were taking greater than 40 mg/day of statins for at least 1
month before and 3 months after allogeneic HSCT (n ¼ 10)
had a numerical reduction in the incidence of grades II to IVdicates regulatory T cell; LFA1, leukocyte function-associated antigen-1; ICAM,
r; MHCII, MHC complex class II; PP, pyrophosphate.
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(10% versus 40%, P ¼ .08) [63]. In a subgroup analysis of 47
acute myeloid leukemia patients, this decrease in acute
GVHD reached statistical signiﬁcance (0% versus 43%, P¼ .02)
[63]. Therewere no differences in chronic GVHD between the
2 groups and no statistically signiﬁcant difference in
progression-free survival in patients with acute myeloid
leukemia, indicating possible preservation of the graft-
versus-leukemia effect with statin therapy [63].
To elucidate the impact of both donor and recipient statin
treatment on GVHD, Rotta et al. conducted 2 retrospective
analyses in allogeneic HSCT patients [64,65]. The ﬁrst study
retrospectively analyzed the impact of both donor and recip-
ient statin treatments on the incidence of acute GVHD in 567
individuals undergoing allogeneic HSCT with HLA-matched
sibling grafts [64]. Speciﬁc statins used by recipients
included atorvastatin (n ¼ 22), simvastatin (n ¼ 5), and rosu-
vastatin (n ¼ 1), and statins used by donors included ator-
vastatin (n ¼ 49), simvastatin (n ¼ 23), rosuvastatin (n ¼ 4),
pravastatin (n ¼ 6), lovastatin (n ¼ 4), and ﬂuvastatin (n ¼ 1)
[64]. In amultivariate analysis, donor statin treatment (n¼ 87)
was associatedwith a reduction in grades III to IV acute GVHD
(hazard ratio [HR] ¼ .28) [64]. When analyzed by subtype
of acute GVHD, researchers found that donor statin use was
associated with a signiﬁcant reduction in gastrointestinal
GVHD (P¼ .02) but not other subtypes [64]. Of note, protection
against GVHD was statistically signiﬁcant in patients who
received cyclosporine-based immunosuppression but not in
those who received tacrolimus-based immunosuppression
[64]. Recipient statin treatment was not associated with
a reduction in the risk of GVHD; however, only 28 recipients
had used statins regularly before allogeneic HSCT [64].
Researchers also examined the composition of peripheral
blood stem cell grafts in 312 patients, and, interestingly, donor
statin exposure was associated with a reduced content of
dendritic cells of the type 2 variety (1.46  106  .46  106
cells/kg, P¼ .002) andno change in the amount of CD34þ stem
cells (.78  106  .48  106 cells/kg, P ¼ .11) [64].
Given the low amount of recipient statin use in the ﬁrst
study, Rotta et al. conducted a second study [65] to examine
the effects of recipient statin treatment by analyzing out-
comes in both related and unrelated donors (N ¼ 1206).
Statins used by recipients in this study included atorvastatin
(n¼ 40), simvastatin (n¼ 16), pravastatin (n¼ 10), lovastatin
(n ¼ 6), and rosuvastatin (n ¼ 4). A multivariate analysis,
adjusted for a number of potential GVHD risk factors,
revealed that statin use was associated not with a reduction
in acute GVHD but with a decreased risk of chronic GVHD
(HR ¼ .62, P ¼ .05) [65]. Similar to the previous retrospective
trial, the decreased risk of GVHD was restricted to patients
who received cyclosporine-based immunosuppression [65].
The authors suggested that this may be a result of synergy
between statins and cyclosporine. Cyclosporine, but not
tacrolimus, interacts with cyclophilins, which affect the
calcium-dependent mitochondrial membrane permeability
transition, a key process in the apoptotic pathway [64]. Sta-
tins also affect this process. However, because the literature
suggests that tacrolimus may be more effective than cyclo-
sporine at preventing GVHD, this may simply reﬂect the
relatively lower potency of statins in preventing GVHD
compared with the choice of calcineurin inhibitor [33].
Additionally, concomitant use of many statins and cyclo-
sporine results in signiﬁcantly increased statin exposure,
most likely because of inhibition of the organic anion trans-
porting polypeptide 1B1 (OATP1B1), a membrane transporterinvolved in statin uptake into the liver [66]. Thus, this dif-
ference may be the result of increased statin exposure in
patients being treated with concomitant cyclosporine. In a
subset analysis of patients on cyclosporine-based prophylaxis
who survived beyond day 100 post-transplant, statin use was
even more strongly associated with protection against
chronic GVHD (HR ¼ .40, P ¼ .02) [65]. However, there was
also a statistically signiﬁcant increased risk of recurrent ma-
lignancy (HR ¼ 2.53, P ¼ .009) in this subset [65]. This
increased risk of disease relapse was not seen in the overall
cohort of patients who received statins or in those who had
received tacrolimus-based GVHD prophylaxis; however,
given that only 76 patients were treated with statins, the
study was likely underpowered to detect a difference in this
outcome [65]. The implications of the increased risk of dis-
ease relapse in this speciﬁc subset of patients are unclear but
certainly warrant further investigation.
Most recently, statins have been evaluated prospectively
in a phase II, single-arm clinical trial as a component of the
GVHD prophylaxis regimen in matched sibling allogeneic
HSCTs (N¼ 30) [67]. Donors received atorvastatin 40mg daily
for 14 to 28 days before leukapheresis, and recipients
received atorvastatin 40 mg daily starting on day 14 and
continuing until immunosuppressionwas stopped, dayþ180,
development of grades II to IV acute GVHD, or the develop-
ment of severe chronic GVHD. The cumulative rates of grades
II to IV acute GVHD were 3.3% at 100 days and 11.1% at 180
days post-transplant [67]. Although difﬁcult to draw deﬁni-
tive conclusionswith this small sample size, the rates of acute
GVHD are considerably lower than those published in the
literature (30% to 50%) [67]. There was also an increase in IL-
10 concentrations after atorvastatin treatment, although this
was not statistically signiﬁcant (n ¼ 17, 5.6 versus 7.1 pg/mL,
P ¼ .06) [67]. IL-10 is an anti-inﬂammatory cytokine charac-
teristic of the TH2 phenotype associated with a reduction in
acute GVHD [68,69]. This increase in IL-10 concentrations is
promising and further supports a possible mechanism for
statin immunomodulation in this setting. Rates of chronic
GVHD were in line with what is expected in this population,
with a 1-year cumulative incidence of 52.3% [67]. Of note,
recipients stopped statin therapy once immunosuppression
was stopped, day þ180, or the development of grades II to IV
acute or severe chronic GVHD. Because the data by Rotta et al.
[65] suggest that statin use post-transplant may reduce
chronic GVHD, it is possible that extending statin therapy
beyond the acute setting may affect chronic GVHDwhile also
potentially impacting cardiovascular morbidity in this at-risk
population. Further, larger studies are required to test this
theory and to conﬁrm any beneﬁts with regards to lowering
of acute GVHD. Most importantly, treatment with statins was
safe. Although the study was not adequately powered to fully
assess safety outcomes, no serious adverse events, increases
in infection, or increases in relapse were noted [67].
The evidence for statin use in allogeneic HSCT patients is
certainly expanding; however, clinicians must be cognizant
of potential drugedrug interactions and adverse reactions
associated with these agents. The major adverse effects
associated with statins include asymptomatic elevations in
hepatic transaminases and myopathy [70]. In the study by
Blaser et al. [21] mentioned previously, 220 allogeneic HSCT
patients were treated with statins within 2 years of trans-
plantation and only 7 patients (3%) discontinued therapy
secondary to potential statin toxicity. Two patients (1%)
developed myopathies, and only 1 patient (.5%) had liver
function test elevations attributable to statin toxicity.
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ered to assess statin toxicity in allogeneic HSCT patients,
clinicians must carefully monitor for liver function test ele-
vations while results from larger, future prospective studies
are awaited. However, it must be noted that these data are in
line with what has been seen the general population, in
which liver enzyme abnormalities occur infrequently
(approximately 1% in postmarketing studies and large meta-
analyses) [71,72]. This low rate of toxicity prompted the US
Food and Drug Administration to remove the recommenda-
tion to routinely monitor liver function tests during statin
therapy, given the paucity of this adverse reaction [73].
Nonetheless, there have been case reports of hepatic failure
associated with statin use, and it is reasonable to monitor
liver function tests periodically in allogeneic HSCT patients,
given the lack of robust, prospective data in this setting [71].
Statin-induced myopathy, ranging from muscle aches to
overt rhabdomyolysis, is also uncommon, occurring at a rate
of .1% to .2% in clinical trials. Fatal rhabdomyolysis is even
more rare, with an estimate occurrence rate of <1 death per
million statin prescriptions [70]. The risk of myopathy ap-
pears to be dose- and concentration-related [70]. Thus,
pharmacokinetic drugedrug interactions that elevate serum
concentrations of statins increase the risk of myopathy.
Most statins, with the exception of pitavastatin, pravas-
tatin, and rosuvastatin, are highly dependent on cytochrome
P-450 (CYP450) enzymes for metabolism and elimination
[66]. Atorvastatin, lovastatin, and simvastatin are metabo-
lized primarily through CYP3A4. Thus, allogeneic HSCT
patients also on azole antifungals which are strong 3A4 in-
hibitors (itraconazole, posaconazole, and voriconazole),
should be closely monitored for toxicity and consideration
should be made for using a non-3A4 metabolized statin for
lipid lowering. All statins appear to be substrates of hepatic
transporter proteins, in particular the organic anion trans-
porting polypeptide, which appears to be the most signiﬁ-
cant transporter involved in statin drugedrug interactions
[66]. As mentioned previously, cyclosporine, an inhibitor of
not only CYP3A4 but also of OATP1B1, increases the area
under the curve of statins by 2- to 25-fold depending on the
particular agent and individual genetic differences in statin
metabolism and elimination [66]. Fluvastatin, a 2C9Table 3
Dosing, Efﬁcacy, Drug Interaction Potential, and Adverse Events of Lipid-Lowering
Agent Dosing Range Lipid-Lowering Efﬁcacy
LDL HDL Tg
Pravastatin 10-80 mg daily ()22-37% (þ)2-12% (
Lovastatin 10-80 mg daily ()21-40% (þ)5-10% (
Simvastatin 5-80 mg daily ()26-47% (þ)8-16% (
Fluvastatin 20-80 mg daily ()22-36% (þ)3-6% (
Pitavastatin 1-4 mg daily ()32-43% (þ)5-8% (
Atorvastatin 10-80 mg daily ()39-60% (þ)5-9% (
Rosuvastatin 5-40 mg daily ()45-63% (þ)8-14% (
Fenoﬁbrate 67-200 mg daily ()20-31% (þ)9-14% (
Gemﬁbrozil 600 mg twice daily ()5-10% (þ)10-20% (
Niacin 1.5-6 g/day ()5-25% (þ)15-25% (
Fish oil 4 g daily (þ)44.5% (þ)9.1% (
Ezetimibe 10 mg daily ()15-20% (þ)1-4% (
Cholesterol absorption
inhibitors
Cholestyramine: 4-24 g/day
Colesevelam: 6-7 tabs/day
Colestipol: 7-30 g/day
()15-30% (þ)3-5% (þ
Data from [54,66,70,71,77-79,84,85]. Tg indicates triglycerides; DDIs, drugedrug in
applicable; SCr, serum creatinine.substrate minimally affected by OATP1B1 in vivo, appears to
be the least affected by cyclosporine, with concomitant
use resulting in an area under the curve increase of
approximately 2- to 4-fold [66]. The incidence of myopathy is
signiﬁcantly increased with concomitant cyclosporine and
most statins; however, when used in the smallest possible
doses with closemonitoring, statins can be used safely in this
setting. Tacrolimus, on the other hand, does not alter the
pharmacokinetics of statins [66]. Table 3 summarizes the
doses, efﬁcacy, pharmacokinetic interaction potential, and
common adverse events of anti-hyperlipidemia agents. By
staying cognizant of potential drugedrug interactions
(Table 4), clinicians can take full advantage of the emerging
beneﬁts of statin use in the setting of allogeneic HSCT.
Other Agents
There are very little data for other anti-hyperlipidemia
medications in the setting of allogeneic HSCT, although this
does not preclude their use in theproper clinical setting. In the
retrospective analysis byKagoya et al. [20] referenced above, 3
patients with dyslipidemia post-allogeneic HSCT were effec-
tively treated with ﬁbrates and 1 patient with niacin. There is
also 1 case report of using bezaﬁbrate in combination with
ursodeoxycholic acid for severe lipoprotein X-mediated hy-
percholesterolemia caused by GVHD and cholestasis [74].
Fibrates act as agonists for peroxisome proliferator-activated
receptor-a, a transcription factor that up-regulates lipolysis,
reduces secretion of VLDL particles, increases free fatty acid
uptake by the liver, and increases high-density lipoprotein
(HDL) plasma levels [75]. Treatment with ﬁbrates result in a
30% to 60% reduction in triglycerides, making these agents
particularly attractive in the setting of sirolimus-induced
dyslipidemia or lipoprotein-X mediated hypercholesterole-
mia, which are characteristically triglyceride-predominant
conditions. Reductions in LDL and increases in HDL are
comparatively smaller, averaging 5% to 31% and 9% to 20%,
respectively [54]. In addition to the effects on lipids, bezaﬁ-
brate has also been used as an effective treatment for chronic
GVHDof the liver inpatients unresponsive to ursodeoxycholic
acid and immunosuppressants [76]. Thus, although the
immunomodulatory effects of ﬁbrates have never been fully
evaluated in the setting of GVHD to the same scale as statins,Agents
Pharmacokinetic DDIs Signiﬁcant AEs
)11-24% OATP substrate Myopathy, increased transaminases
)10-19% OATP, 3A4 substrate
)12-33% OATP, 3A4 substrate
)12-18% OATP, 2C9 substrate
)15-19% OATP, UGT substrate
)19-37% OATP, 3A4 substrate
)10-35% OATP substrate
)30-50% N/A Dyspepsia, increased transaminases,
increased SCr (fenoﬁbrate))40-60% Inhibits 1A2, 2C8, 2C9,
2C19, and OATP
)20-50% N/A Flushing, hepatotoxicity, glucose
intolerance, hyperuricemia
)44.9% N/A Dyspepsia, increased bleeding risk
)5-8% OATP substrate Diarrhea
)0-20% May decrease absorption
of other agents
Constipation, bloating, ﬂatulence
teractions; AEs, adverse events; UGT, UDP-glucuronosyltransferase; N/A, not
Table 4
Drug Interactions with Common Allogeneic HSCT Medications
Cyclosporine Tacrolimus Sirolimus Azole
Antifungals
Pravastatin XXX (limit
pravastatin
to 20 mg/day)
d d d
Lovastatin CI/avoid d d CI e itra,
posa, vori
XX e ﬂuc
Simvastatin CI/avoid d d CI e itra,
posa, vori
XX e ﬂuc
Fluvastatin XXX (limit
ﬂuvastatin to
20 mg/day)
d d XXX e limit
to 20 mg/day
with ﬂuc
XX e vori
Pitavastatin CI/avoid d d d
Atorvastatin CI/avoid XXX e limit
to 20 mg/day
with itra,
posa, vori
Rosuvastatin XXX (limit
rosuvastatin
to 5 mg/day)
d d d
Fenoﬁbrate
and
gemﬁbrozil
XX (both can
cause renal
dysfunction)
XX (both can
cause renal
dysfunction)
d d
Niacin d d d d
Cholesterol
absorption
inhibitors
XXX (separate
administration)
X (could theoretically decrease
absorption)
Ezetimibe XXX d d d
Data from [54]. XXX indicates strong interaction;d, no clinically signiﬁcant
interaction; CI, contraindicated; itra, itraconazole; posa, posaconazole; vori,
voriconazole; XX, moderate interaction; ﬂuc, ﬂuconazole; X, mild
interaction.
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ruled out. Fibrates are generally well tolerated, most
commonly causing gastrointestinal upset and asymptomatic
liver enzyme elevations [54]. However, concomitant use of
these agents with statins does increase the risk for myopathy
primarily through inhibition of hepatic uptake of statins via
OATP1B1 [66]. In addition, fenoﬁbrate has been associated
with reversible increases in serum creatinine [77].
Niacin has been used for a number of years in the treat-
ment of dyslipidemia, and its exact mechanism in this regard
is complex and not fully understood [78]. Treatment with
niacin results in a 5% to 25% reduction in LDL cholesterol, a
20% to 50% reduction in triglycerides, and is the most effec-
tive agent in raising HDL cholesterol, resulting in a 15% to 35%
increase in levels [54]. Although niacin has signiﬁcant
favorable effects on all cholesterol subtypes, tolerability
limits its widespread use. Niacin is associatedwith cutaneous
ﬂushing in up to 90% of patients [78]. Sustained-release
preparations are associated with a lower incidence of this
adverse reaction but have less of an impact on lipid param-
eters and pose an increased risk of rare hepatotoxicity. Other
problematic adverse reactions include hyperuricemia,
glucose intolerance, and gastrointestinal disturbances [79].
There is limited evidence for the use of niacin in the alloge-
neic HSCT population, but niacin is not associated with sig-
niﬁcant pharmacokinetic drugedrug interactions, making it
a particularly attractive choice in patients on cyclosporine or
azole antifungals. There is some emerging evidence that
niacin possesses anti-inﬂammatory activity through its ac-
tivity at the G proteinecoupled receptor GPR109A (hydroxyl-
carboxylic acid receptor 2) [78]. This receptor is expressednot only on adipocytes but also on neutrophils, macrophages,
and Langerhans cells. Through this pathway, niacin has been
shown to suppress secretion of inﬂammatory cytokines,
including MCP-1, regulated on activation, normal T cell
expressed and secreted (RANTES), fractalkine, TNF-a, and IL-
6 [78]. Because some of these cytokines play a clear role in
the pathogenesis of GVHD, niacin may possess beneﬁts
beyond simply effective management of multiple lipid ab-
normalities. If tolerated, its use in the allogeneic HSCT setting
should be accompanied by monitoring for glucose intoler-
ance and hyperuricemia.
n-3 Polyunsaturated fatty acids (n-3 PUFAs, or “ﬁsh oils”),
including docosahexaenoic acid and eicosapentaenoic acid,
are particularly effective agents at reducing triglycerides.
Lovaza is a ﬁsh oil product approved by the US Food and Drug
Administration as an adjunct to diet to reduce triglyceride
levels in patients with severe hypertriglyceridemia [80].
Studies of Lovaza in this population resulted in a nearly 45%
decrease in triglyceride levels [80]. The mechanism of lipid
lowering by n-3 PUFAs is thought to be related to inhibition
of fatty acid and triglyceride biosynthesis, reduction in
hormone-sensitive lipase activity, and stimulation of fatty
acid oxidation [81]. Interestingly, n-3 PUFAs are also thought
to have immunomodulatory effects. n-3 PUFAs alter the
phospholipid content of inﬂammatory cells, resulting in a
decreased production of arachidonic acidederived inﬂam-
matory prostaglandins, thromboxanes, and leukotrienes and
an increased production of the anti-inﬂammatory resolvins
[82]. n-3 PUFAs have also been shown to decrease leukocyte
chemotaxis, inﬂammatory cytokine production, adhesion
molecule expression, and reactive oxygen species generation
[82]. n-3 PUFAs have demonstrated clinical beneﬁt in several
inﬂammatory conditions, including rheumatoid arthritis,
inﬂammatory bowel disease, asthma, and acute lung injury
in intensive care unit patients [82,83]. Thus, although evi-
dence for their use in the allogeneic HSCT population is
lacking, a potential anti-inﬂammatory effect in patients at
risk for GVHD is intriguing. Of note, n-6 PUFAs, including
linoleic acid and arachidonic acid, have been shown to be
pro-inﬂammatory. There are no expected pharmacokinetic
interactions of n-3 PUFAs with commonly used transplant
medications; the main concern with using these agents in
the allogeneic HSCT setting is the potential for inhibition of
platelet aggregation induced by PUFA byproducts [84]. Thus,
allogeneic HSCT patients inwhom n-3 PUFAs are used should
be monitored closely for bleeding, and these agents should
be used cautiously in patients with signiﬁcant thrombocy-
topenia or other concomitant antiplatelet agents.
Ezetimibe inhibits the Niemann-Pick C1-like transporter
in the intestinal tract, preventing cholesterol absorption [85].
Treatment with ezetimibe results in a moderate decrease in
LDL of approximately 20%, a decrease in triglycerides of up to
8%, and a 1% to 4% increase in HDL [54]. Ezetimibe is
frequently combined with statins for additive LDL lowering.
Ezetimibe has also been shown to reduce inﬂammatory
markers in patients with hyperlipidemia, but the mechanism
for this anti-inﬂammatory effect has not been elucidated
[85,86]. The reduction in inﬂammation may simply result
from a reduction in lipid values. Ezetimibe is typically well
tolerated, with diarrhea being the most common complaint
(occurring in approximately 4% of patients), and this agent
can be used safely in combination with statins to gain addi-
tional LDL lowering efﬁcacy [87,88]. Although this agent has
not been systematically evaluated in the allogeneic HSCT
population, it appears to be a safe and attractive option for
Table 5
Potential Immunomodulatory Effects of Lipid-Lowering Agents
Agent Effects
Pravastatin 1. Promotes TH2 phenotype by inhibiting Ras, Rac, and
Rho formation [55,56]
2. Blocks LFA-1, preventing T cell-to-APC interaction
[58,59]
3. Alters APC function and proliferation [17,60,61]
4. Up-regulates anti-inﬂammatory T regulatory cell
expression [57]
Lovastatin
Simvastatin 1. Promotes TH2 phenotype by inhibiting Ras, Rac, and
Rho formation [55,56]
2. Alters APC function and proliferation [17,60,61]
3. Up-regulates anti-inﬂammatory T regulatory cell
expression [57]
Fluvastatin
Pitavastatin
Atorvastatin
Rosuvastatin
Fenoﬁbrate 1. Bezaﬁbrate shows evidence for chronic GVHD re-
fractory to ursodeoxycholic acid [76]Gemﬁbrozil
Niacin 1. Suppresses secretion of inﬂammatory cytokines
through the GPR109A receptor [78]
Fish oil
(n-3
PUFAs)
1. Decreases production of prostaglandins, thrombox-
anes, and leukotrienes [82]
2. Increases production of the anti-inﬂammatory
resolvins [82]
3. Decreases leukocyte chemotaxis, inﬂammatory cyto-
kine production, adhesion molecule expression, and
ROS generation [82]
NOTE: n-6 PUFAs may be pro-inﬂammatory [84]
Ezetimibe 1. May decrease vascular inﬂammation [85,86]
Cholesterol
absorption
inhibitors
N/A
ROS indicates reactive oxygen species.
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setting of drugedrug interactions. Ezetimibe is not metabo-
lized via CYP enzymes; however, like many statins, it is
handled by the OATP1B1 transporter [89]. Cyclosporine, an
OATP1B1 inhibitor, has been shown to increase ezetimibe
concentrations 2- to 3-fold [54]. Thus, the combination of
ezetimibe and cyclosporine should be used with caution. The
gastrointestinal adverse effects of this agentmay preclude its
use in patients with gastrointestinal GVHD, and this agent
should be discontinued if gastrointestinal GVHD is
suspected.
The ﬁnal class of agents, the bile acid sequestrants, act
by binding and preventing reabsorption of bile acids in the
gastrointestinal lumen. This results in increased uptake and
breakdown of LDL cholesterol in the liver for conversion
into bile acids [85]. Treatment with bile acid sequestrants
results in a 15% to 30% decrease in LDL and a 3% to 5% in-
crease in HDL [54]. In combination with statins, these
agents result in a nearly 50% lowering of LDL [85]. Unfor-
tunately, bile acid sequestrants can result in up to a 20%
increase in triglycerides, so caution must be used in pa-
tients with severe hypertriglyceridemia [85]. In addition,
the bile acid sequestrants are sometimes difﬁcult to
tolerate and inconvenient, requiring multiple doses per
day. The main side effects are gastrointestinal in nature and
include constipation, bloating, and ﬂatulence [85]. In
addition to binding bile acids, these agents also bind many
drugs in the gastrointestinal tract, resulting in decreased
systemic exposure to some agents. Interacting medications,
including cyclosporine, should be given at least 1 hour
before and 4 hours after bile acid sequestrants [85]. These
agents have also not been systematically evaluated in the
allogeneic HSCT population.
The hydrophilic bile acid ursodiol, although not typically
thought of as a lipid-lowering agent, may have a similar
mechanism of action to the bile acid sequestrants. It has been
hypothesized that ursodiol may reduce gastrointestinal ab-
sorption of cholesterol, increase receptor-mediated LDL up-
take in the liver, and potentially inhibit HMG-CoA reductase
[90-92]. This agent also reduces the concentration of hepa-
totoxic hydrophobic bile acids and may possess immuno-
modulatory effects, including a reduction in the production of
the inﬂammatory cytokines TNF-a, macrophage inﬂamma-
tory protein 2, and IL-6 [93-96]. Accordingly, prophylactic
ursodiol given for 90 days post-allogeneic HSCT (N¼ 242) has
been shown to result in a reduction in grades III to IV acute
GVHD, grades II to IV and III to IV liver GVHD, grades III to IV
skin GVHD, and grades II to IV gastrointestinal GVHD [96].
Most importantly, ursodiol given in this manner resulted in a
signiﬁcantly higher overall survivalwith 10 years of follow-up
(38% versus 48%, P¼ .037) with no difference in the incidence
of relapse [97]. In patients with primary biliary cir-
rhosisdoften associated with hypercholesterolemiadtreat-
ment with ursodiol has been shown to result in a 28%
reduction in total cholesterol at 2 years [98]. To test whether
this effect was due to improvement in the underlying chole-
static liver disease or an intrinsic lipid-lowering property of
ursodiol, Braga et al. [99] conducted a multicenter, random-
ized, placebo-controlled, double-blind clinical trial in 125
patients with primary hypercholesterolemia without under-
lying liver disease. Unfortunately, ursodiol had no effect on
lipid values throughout the 24 weeks of treatment. Thus,
although ursodiol is a key agent that should be given post-
transplant, it does not possess intrinsic lipid-lowering prop-
erties in those with hypercholesterolemia not induced bycholestatic liver disease. Table 5 summarizes the hypothe-
sized immunomodulatory activity of individual statins and
other anti-hyperlipidemia medications.
SUMMARY AND RECOMMENDATIONS
The incidence of dyslipidemia and CVD post-allogeneic
HSCT is coming to the forefront as a signiﬁcant long-term
complication worthy of serious consideration. Data indicate
that these complications are not only frequent but occur
much earlier than expected in the general population. Based
on clinical practice guidelines for the management of dysli-
pidemia, patients at high risk of CVD should receive mod-
erate to high doses of statins because of the reduction in
mortality seen in this setting. Overwhelmingly, the data
indicate that allogeneic HSCT patients are at a signiﬁcantly
greater risk of CVD compared with the general population
and thus could potentially beneﬁt from statin therapy,
regardless of calculated risk based on age and traditional risk
measures in the Pooled Cohort Equations. Of the anti-
hyperlipidemia medications, statins have the most evi-
dence in the allogeneic HSCT population and have been used
safely to effectively manage dyslipidemia in this setting. Care
should be taken to avoid drugedrug interactions that may
increase the myopathy risk, especially with certain azole
antifungals and the calcineurin inhibitor cyclosporine. With
these considerations in mind, we recommend statins as ﬁrst-
line therapy. Other agents are reasonable choices in the case
of severe isolated hypertriglyceridemia (ﬁbrates) or intoler-
ance, drug interactions, or contraindications to statins. We
recommend monitoring lipid values before transplant and
then every 3 to 4 months thereafter.
Although lowering of cardiovascular risk should be a
primary goal of lipid-lowering therapy in this population,
B.L. Marini et al. / Biol Blood Marrow Transplant 21 (2015) 809e820818several of these agents possess unique immunomodulatory
effects that require further investigation. In particular, statins
may modulate GVHD by down-regulating the TH1 response,
up-regulating regulatory T cell development, and altering
APC function, proliferation, and interaction with T cells.
Phase II trials are currently underway to determine the
effect of statins on GVHD, both as donor pretreatment
(NCT01525407, NCT01527045) and recipient GVHD prophy-
laxis (NCT01175148, NCT01491958). Because of the beneﬁts
of statins with regards to CVD morbidity and mortality as
well as the increasing clinical evidence for their role in
modulation of GVHD, these agents should be strongly
considered in patients undergoing allogeneic HSCT able to
tolerate therapy. Clinicians must remain aware of the po-
tential toxicities and drug interactions with statin therapy as
well as the unknown effects on relapse. Ongoing trials will
deﬁnitively answer this question in the near future. Finally,
although management of dyslipidemia is a critical need in
this population, CVD risk factors frequently coexist; thus,
management and prevention of CVD should always occur as
a part of a comprehensive cardiac risk management program
that addresses all major modiﬁable risk factors.ACKNOWLEDGMENTS
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